Compare TRTX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | CRMD |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.2M | 590.7M |
| IPO Year | 2015 | 2009 |
| Metric | TRTX | CRMD |
|---|---|---|
| Price | $8.05 | $8.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $9.83 | ★ $14.83 |
| AVG Volume (30 Days) | 835.2K | ★ 884.7K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | 0.19 | ★ 0.43 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $8.78 | $0.30 |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $41.84 | ★ $16.58 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $7.57 | $6.13 |
| 52 Week High | $9.85 | $14.96 |
| Indicator | TRTX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 54.63 |
| Support Level | $8.04 | $7.09 |
| Resistance Level | $8.74 | $9.02 |
| Average True Range (ATR) | 0.19 | 0.35 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 17.50 | 48.67 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.